Related Experiment Video

Updated: Mar 19, 2026

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

2.4K

Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma

Hilary Glen1

  • 1Department of Medical Oncology, Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow, G12 OYN, UK.

Future Oncology (London, England)
|June 25, 2016
PubMed

Insights

Lenvatinib, a multi-kinase inhibitor, shows promise in treating metastatic renal cell carcinoma (mRCC). Combining lenvatinib with everolimus significantly improved progression-free survival in patients resistant to prior therapies.

Area of Science:

  • Oncology
  • Pharmacology
  • Translational Medicine

Background:

  • Metastatic renal cell carcinoma (mRCC) presents challenges due to therapeutic resistance.
  • Current treatments targeting single pathways often lead to eventual disease progression.

Purpose of the Study:

  • To review the clinical development of lenvatinib in mRCC.
  • To explore the potential of multi-pathway inhibition for improved patient outcomes in mRCC.

Main Methods:

  • A randomized Phase II trial was conducted.
  • Patients with mRCC who progressed after one prior VEGF-targeted therapy were evaluated.

Main Results:

  • Lenvatinib, alone or with everolimus, significantly improved progression-free survival compared to everolimus alone.
  • Simultaneous targeting of multiple oncogenic pathways demonstrated clinical benefit.

Conclusions:

  • Lenvatinib plus everolimus represents a promising second-line treatment option for mRCC.
  • Multi-targeted therapies may overcome resistance mechanisms in metastatic renal cell carcinoma.
Keywords:
FGFRVEGFReverolimuslenvatinibmTORrenal cell carcinoma

More Related Videos

Laparoscopic Anatomical Resection of the Right Anterior Lobe Based on the Laennec Capsule Technique06:11

Laparoscopic Anatomical Resection of the Right Anterior Lobe Based on the Laennec Capsule Technique

Published on: May 2, 2025

683
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-308:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.6K

Related Concept Videos

Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
566
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Renal Drug Excretion: Overview01:15

Renal Drug Excretion: Overview

As primary excretory organs, the kidneys maintain homeostasis by removing waste substances from the bloodstream. They comprise over a million units called nephrons, which serve as the kidney's functional units.
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules...
919
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K